Floatz logo

Tucatinib

ER Positive Breast Cancer

Dana-Farber Cancer InstituteSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

76 Active assets in the ER Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Capivasertib
Imperial College London
Phase 2BB

View all 50 →

Same molecule, other indications

Tucatinib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
invasive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →